RÉSUMÉ
RATIONALE: TAFRO syndrome is a systemic inflammatory disorder, manifesting as thrombocytopenia (t), anasarca (a), fever (f), reticulin myelofibrosis/renal insufficiency (r), and organomegaly (o), and considered as a unique clinical subtype of idiopathic multicentric Castleman disease (iMCD). Such syndrome gave rise to a clinical picture similar to that of either a connective tissue disease or an autoimmune disease. PATIENT CONCERNS: A Chinese young female initially presenting with arthralgia, Raynaud phenomenon, generalized edema, and a positive anti-small nuclear ribonucleoprotein particle antibody was diagnosed as mixed connective tissue disease. The kidney biopsy showed thrombotic microangiopathy. Bone marrow smear showed bone marrow hyperplasia and biopsy revealed suspected light chain restricted expression, megakaryocyte proliferation, and moderate to severe bone marrow fibrosis. A lymph node biopsy was conducted and the histopathological findings were consistent with the subtype of mixed Castleman disease. The clinical symptoms were relieved after regular chemotherapy. DIAGNOSES: After above examination results and clinical manifestations, the final diagnoses was TAFRO syndrome. INTERVENTION: The she was started on chemotherapy with bortezomib, cyclophosphamide, and dexamethasone. OUTCOME: After chemotherapy, symptoms such as thrombocytopenia, hematuria and proteinuria disappeared, lymphadenopathy and VEGF level decreased, and bone marrow fibrosis relieved. LESSONS: Our case illustrated the first cases of shared characteristics of mixed connective tissue disease and iMCD-TAFRO syndrome. Cytokines may play a role in the shared pathogenicity of the iMCD-TAFRO syndrome and systemic autoimmune diseases. Therapy directly against inflammatory factors such as corticosteroids or chemotherapy have an important therapeutic implication.
Sujet(s)
Hyperplasie lymphoïde angiofolliculaire , Retard de diagnostic , Thrombopénie , Humains , Femelle , Hyperplasie lymphoïde angiofolliculaire/diagnostic , Hyperplasie lymphoïde angiofolliculaire/traitement médicamenteux , Hyperplasie lymphoïde angiofolliculaire/anatomopathologie , Thrombopénie/diagnostic , Syndrome , Cyclophosphamide/usage thérapeutique , Fièvre/étiologie , Oedème/diagnostic , Oedème/étiologie , Bortézomib/usage thérapeutique , Adulte , Dexaméthasone/usage thérapeutiqueSujet(s)
Lymphome B diffus à grandes cellules , Tumeurs primitives multiples , Humains , Mâle , Sujet âgé , Lymphome B diffus à grandes cellules/anatomopathologie , Lymphome B diffus à grandes cellules/génétique , Lymphome B diffus à grandes cellules/métabolisme , Tumeurs primitives multiples/anatomopathologie , Tumeurs primitives multiples/génétique , Lymphome T/anatomopathologie , Lymphome T/génétique , Lymphome T/métabolisme , Tumeurs gastro-intestinales/anatomopathologie , Tumeurs gastro-intestinales/métabolisme , Tumeurs gastro-intestinales/génétique , Intestin grêle/anatomopathologie , Cyclophosphamide/usage thérapeutique , Vincristine/usage thérapeutique , Doxorubicine/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Diagnostic différentiel , Prednisone/usage thérapeutiqueRÉSUMÉ
Cyclophosphamide (CTX) is the most commonly used effective alkylating drug in cancer treatment, but its use is restricted because its toxic side effect causes testicular toxicity. CTX disrupts the tissue redox and antioxidant balance and the resulting tissue damage causes oxidative stress. In our study based on this problem, kefir against CTX-induced oxidative stress and testicular toxicity were investigated. Rats were divided into 6 groups: control, 150 mg/kg CTX, 5 and 10 mg/kg kefir, 5 and 10 mg/kg kefir + 150 CTX. While the fermented kefirs were mixed and given to the rats for 12 days, CTX was given as a single dose on the 12th day of the experiment. Testis was scored according to spermatid density, giant cell formation, cells shed into tubules, maturation disorder, and atrophy. According to our biochemical findings, the high levels of total oxidant status (TOS), and the low levels of total antioxidant status (TAS) in the CTX group, which are oxidative stress markers, indicate the toxic effect of CTX, while the decrease in TOS levels and the increase in TAS levels in the kefir groups indicate the protective effect of kefir. In the CTX-administered group, tubules with impaired maturation and no spermatids were observed in the transverse section of the testicle, while in the kefir groups, the presence of near-normal tubule structures and tubule lumens despite CTX showed the protective effect of kefir. In our study, it was observed that kefir had a protective and curative effect on CTX-induced toxicity and oxidative stress and could be a strong protector.
Sujet(s)
Antioxydants , Cyclophosphamide , Kéfir , Stress oxydatif , Testicule , Animaux , Mâle , Cyclophosphamide/toxicité , Cyclophosphamide/effets indésirables , Testicule/effets des médicaments et des substances chimiques , Testicule/métabolisme , Testicule/anatomopathologie , Antioxydants/pharmacologie , Antioxydants/métabolisme , Rats , Stress oxydatif/effets des médicaments et des substances chimiques , Oxydants/métabolisme , Antinéoplasiques alcoylants/toxicité , Antinéoplasiques alcoylants/effets indésirables , Rat WistarRÉSUMÉ
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 µg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle of R-CHOP, 25 of whom received blinatumomab. After blinatumomab induction, five (20%) patients achieved CR, four (16%) achieved partial response, and six (24%) were stable. Considering the entire strategy, the overall response rate in the full-analysis-set was 46% (n = 18), with CR in 14 (36%) patients. The most common treatment-emergent adverse events of all grades in the blinatumomab-safety-set included fever (36%), anaemia (24%), and lymphopaenia (24%). Cytokine release syndrome (grade 1/2) was observed in 16% and neurotoxicity in 20% of patients. Blinatumomab demonstrated encouraging anti-tumour activity (the trial met its primary endpoint) and acceptable toxicity in patients with RT.
Sujet(s)
Anticorps bispécifiques , Protocoles de polychimiothérapie antinéoplasique , Cyclophosphamide , Doxorubicine , Lymphome B diffus à grandes cellules , Prednisone , Rituximab , Vincristine , Humains , Mâle , Femelle , Anticorps bispécifiques/administration et posologie , Anticorps bispécifiques/effets indésirables , Anticorps bispécifiques/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Adulte d'âge moyen , Cyclophosphamide/usage thérapeutique , Cyclophosphamide/administration et posologie , Cyclophosphamide/effets indésirables , Rituximab/administration et posologie , Rituximab/usage thérapeutique , Rituximab/effets indésirables , Doxorubicine/usage thérapeutique , Doxorubicine/administration et posologie , Doxorubicine/effets indésirables , Sujet âgé , Prednisone/usage thérapeutique , Prednisone/administration et posologie , Prednisone/effets indésirables , Vincristine/usage thérapeutique , Vincristine/effets indésirables , Vincristine/administration et posologie , Lymphome B diffus à grandes cellules/traitement médicamenteux , Adulte , Sujet âgé de 80 ans ou plus , Leucémie chronique lymphocytaire à cellules B/traitement médicamenteux , Résultat thérapeutiqueRÉSUMÉ
Immunodeficiency can disrupt normal physiological activity and function. In this study, donkey bone collagen peptide (DP) and its iron chelate (DPI) were evaluated their potential as immunomodulators in cyclophosphamide (Cytoxan®, CTX)-induced Balb/c mice. The femoral tissue, lymphocytes, and serum from groups of mice were subjected to hematoxylin and eosin (H&E) staining, methylthiazolyldiphenyl-tetrazolium bromide (MTT) cell proliferation assays, and enzyme-linked immunosorbent assay (ELISA), respectively. Furthermore, a non-targeted metabolomics analysis based on UPLC-MS/MS and a reverse transcription polymerase chain reaction (RT-qPCR) technology were used to explore the specific metabolic pathways of DPI regulating immunocompromise. The results showed that CTX was able to significantly reduce the proliferative activity of mouse splenic lymphocytes and led to abnormal cytokine expression. After DP and DPI interventions, bone marrow tissue damage was significantly improved. In particular, DPI showed the ability to regulate the levels of immune factors more effectively than Fe2+ and DP. Furthermore, metabolomic analysis in both positive and negative ion modes showed that DPI and DP jointly regulated the levels of 20 plasma differential metabolites, while DPI and Fe2+ jointly regulated 14, and all 3 jointly regulated 10. Fe2+ and DP regulated energy metabolism and pyrimidine metabolism pathways, respectively. In contrast, DPI mainly modulated the purine salvage pathway and the JAK/STAT signaling pathway, which are the key to immune function. Therefore, DPI shows more effective immune regulation than Fe2+ and DP alone, and has good application potential in improving immunosuppression.
Sujet(s)
Collagène , Cyclophosphamide , Equidae , Agents chélateurs du fer , Souris de lignée BALB C , Animaux , Collagène/métabolisme , Agents chélateurs du fer/pharmacologie , Souris , Prolifération cellulaire/effets des médicaments et des substances chimiques , Peptides/pharmacologie , Lymphocytes/effets des médicaments et des substances chimiques , Lymphocytes/métabolisme , Immunosuppresseurs/pharmacologie , Métabolomique , Cytokines/métabolisme , Mâle , Os et tissu osseux/effets des médicaments et des substances chimiques , Os et tissu osseux/métabolisme , Immunosuppression thérapeutiqueRÉSUMÉ
Dose optimization of sirolimus may further improve outcomes in allogeneic hematopoietic cell transplant (HCT) patients receiving post-transplantation cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD). Sirolimus exposure-response association studies in HCT patients (i.e., the association of trough concentration with clinical outcomes) have been conflicting. Sirolimus has important effects on T-cells, including conventional (Tcons) and regulatory T-cells (Tregs), both of which have been implicated in the mechanisms by which PTCy prevents GVHD, but there is an absence of validated biomarkers of sirolimus effects on these cell subsets. Considering the paucity of existing biomarkers and the complexities of the immune system, we conducted a literature review to inform a quantitative systems pharmacology (QSP) model of GVHD. The published literature presented multiple challenges. The sirolimus pharmacokinetic models insufficiently describe sirolimus distribution to relevant physiological compartments. Despite multiple publications describing sirolimus effects on Tcons and Tregs in preclinical and human ex vivo models, consistent parameters relating sirolimus concentrations to circulating Tcons and Tregs could not be found. Each aspect presents a challenge in building a QSP model of sirolimus and its temporal effects on T-cell subsets and GVHD prevention. To optimize GVHD prevention regimens, phase I studies and systematic studies of immunosuppressant concentration-effect association are needed for QSP modeling.
Sujet(s)
Cyclophosphamide , Maladie du greffon contre l'hôte , Transplantation de cellules souches hématopoïétiques , Immunosuppresseurs , Sirolimus , Humains , Sirolimus/administration et posologie , Maladie du greffon contre l'hôte/prévention et contrôle , Maladie du greffon contre l'hôte/immunologie , Transplantation de cellules souches hématopoïétiques/effets indésirables , Transplantation de cellules souches hématopoïétiques/méthodes , Cyclophosphamide/effets indésirables , Immunosuppresseurs/administration et posologie , Immunosuppresseurs/pharmacocinétique , Lymphocytes T régulateurs/immunologie , Lymphocytes T régulateurs/effets des médicaments et des substances chimiques , Animaux , Modèles biologiquesRÉSUMÉ
Granulomatosis with polyangiitis (GPA) is a pauci-immune vasculitis typically involving upper and lower respiratory tract involvement and crescentic glomerulonephritis. Salivary gland involvement in GPA is rare. When it occurs in GPA, it is commonly seen with sinonasal and lung involvement and rarely with renal involvement. Easy accessibility of salivary glands allows early biopsy and timely treatment. In our case with GPA, salivary gland involvement was unresponsive to cyclophosphamide but remitted with rituximab.
Sujet(s)
Granulomatose avec polyangéite , Rituximab , Sialadénite , Humains , Sialadénite/diagnostic , Granulomatose avec polyangéite/diagnostic , Granulomatose avec polyangéite/traitement médicamenteux , Granulomatose avec polyangéite/complications , Rituximab/usage thérapeutique , Cyclophosphamide/usage thérapeutique , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/diagnostic , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/complications , Mâle , Anticorps anti-cytoplasme des polynucléaires neutrophiles/sang , Anticorps anti-cytoplasme des polynucléaires neutrophiles/immunologie , Immunosuppresseurs/usage thérapeutique , Adulte d'âge moyen , FemelleRÉSUMÉ
BACKGROUND AND PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a troublesome side effect in patients exposed to taxanes in the treatment of cancer and may affect quality of life dramatically. Here we assessed whether serum levels of neurofilament light (NfL) and tau (two neuroaxonal injury biomarkers) and glial fibrillary acidic protein (GFAP, a biomarker for astrocytic activation) correlate with the development of CIPN in the adjuvant setting of early breast cancer. MATERIALS AND METHODS: Using ultrasensitive single molecule array technology, serum levels of NfL, GFAP, and tau were measured before and every 3 weeks in 10 women receiving adjuvant EC (epirubicin 90 mg/m² and cyclophosphamide 600 mg/m²) every 3 weeks × 3, followed by weekly paclitaxel 80 mg/m² × 9-12 weeks after surgery due to early breast cancer. CIPN was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0) and the questionnaire EORTC QLQ CIPN-20. RESULTS: Serum levels of GFAP increased successively during cycles of EC. NfL increased instead in response to the treatment of paclitaxel. NfL and GFAP continued to rise throughout exposure of cumulatively higher doses of paclitaxel and were reduced 3 months after the end of chemotherapy. Serums levels of tau were marginally affected by exposure to chemotherapy. Women with worse symptoms of CIPN had higher concentrations of NfL than women with mild symptoms of CIPN. INTERPRETATION: NfL and GFAP are promising biomarkers to identify women at risk of developing CIPN. Larger prospective studies are now needed.
Sujet(s)
Marqueurs biologiques , Tumeurs du sein , Épirubicine , Protéine gliofibrillaire acide , Protéines neurofilamenteuses , Paclitaxel , Neuropathies périphériques , Protéines tau , Humains , Femelle , Neuropathies périphériques/induit chimiquement , Neuropathies périphériques/sang , Neuropathies périphériques/diagnostic , Tumeurs du sein/traitement médicamenteux , Tumeurs du sein/sang , Protéines neurofilamenteuses/sang , Adulte d'âge moyen , Protéine gliofibrillaire acide/sang , Paclitaxel/effets indésirables , Paclitaxel/administration et posologie , Protéines tau/sang , Adulte , Marqueurs biologiques/sang , Épirubicine/effets indésirables , Épirubicine/administration et posologie , Astrocytes/effets des médicaments et des substances chimiques , Astrocytes/anatomopathologie , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Cyclophosphamide/effets indésirables , Cyclophosphamide/administration et posologie , Sujet âgé , Traitement médicamenteux adjuvant/effets indésirablesRÉSUMÉ
BACKGROUND: The chemotherapy regimens recommended for both rhabdomyosarcoma (RMS) and Ewing sarcoma (ES) patients are myelosuppressive and can reduce the absolute neutrophil count (ANC) and subsequently increase the risk of febrile neutropenia (FN). However, only a few studies have focused on the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) drugs in pediatric and adolescent patients with RMS and ES. Our objective was to investigate the efficacy and safety of mecapegfilgrastim, a biosimilar of pegfilgrastim, in prophylaxis of FN for pediatric and adolescent patients with RMS or ES. METHODS: In this single-arm, single-center, prospective study, pediatric and adolescent patients with RMS or ES were enrolled to receive either VAC (vincristine, cyclophosphamide, dactinomycin) regimen or VDC (vincristine, cyclophosphamide, doxorubicin) regimen in a 3-week cycle, followed by treatment with mecapegfilgrastim (100 µg/kg, maximum 6 mg) given at 24 h after completing chemotherapy. The primary endpoint was the incidence rate of FN. Secondary endpoints included the incidence rate of grade 4 neutropenia, duration of ANC ≤ 0.5 × 109/L, incidence rate of chemotherapy delay or reduction, use of antibiotics, and safety profile. RESULTS: In total, 2 of the 30 (6.7%, 95% CI: 0.82-22.07) patients experienced FN after the first cycle of chemotherapy. Eight (26.7%, 95% CI: 12.28-45.89) patients experienced grade 4 neutropenia after receiving prophylactic mecapegfilgrastim. Eight patients experienced ANC ≤ 0.5 × 109/L with a median duration of 4.5 days; among them, 6 patients reached the lowest point of their ANC level on day 7, and 5 of them recovered by day 10. No dose reductions, delays, or discontinuation of chemotherapy was reported. Twenty-one (70.0%) patients received antibiotics during the treatment period. No patient experienced FN in the 0-5 years and the 13-18 years groups, and 2 patients experienced FN in the 6-12 years group. Two patients, 6 patients, and no patient experienced grade 4 neutropenia in the 0-5 years, 6-12 years, and 13-18 years groups, respectively. CONCLUSION: Mecapegfilgrastim showed acceptable efficacy and safety profile in pediatric and adolescent patients with RMS or ES. Further randomized studies with large sample size are warranted. TRIAL REGISTRATION: This clinical trial was registered at Chictr.org.cn (No.ChiCTR1900022249). Registered on March 31, 2019.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Neutropénie fébrile , Filgrastim , Rhabdomyosarcome , Sarcome d'Ewing , Humains , Mâle , Femelle , Adolescent , Sarcome d'Ewing/traitement médicamenteux , Enfant , Projets pilotes , Études prospectives , Enfant d'âge préscolaire , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Rhabdomyosarcome/traitement médicamenteux , Neutropénie fébrile/prévention et contrôle , Neutropénie fébrile/induit chimiquement , Neutropénie fébrile/étiologie , Filgrastim/usage thérapeutique , Filgrastim/administration et posologie , Filgrastim/effets indésirables , Cyclophosphamide/effets indésirables , Cyclophosphamide/administration et posologie , Cyclophosphamide/usage thérapeutique , Dactinomycine/administration et posologie , Dactinomycine/effets indésirables , Dactinomycine/usage thérapeutique , Doxorubicine/effets indésirables , Doxorubicine/administration et posologie , NourrissonRÉSUMÉ
Objective: To investigate the clinical manifestations, endoscopic characteristics, and prognostic factors of patients with colorectal extranodal NK/T cell lymphoma. Methods: The clinical data of 52 patients with colorectal extranodal NK/T cell lymphoma admitted to the First Affiliated Hospital of Zhengzhou University from January 2013 to January 2023 were retrospectively analyzed. Their clinical manifestations and endoscopic characteristics were summarized, and the prognostic factors were analyzed by Cox regression model. Results: Among the 52 patients with colorectal extranodal NK/T cell lymphoma, there were 35 males and 17 females, with a male-to-female ratio of 2.06â¶1. Among the general symptoms, abdominal pain was the most common (39 cases), and B symptoms occurred in 47 patients, among which fever was the most common lymphoma B symptom (42 cases), and gastrointestinal perforation was the most common complication (18 cases). Forty-three patients underwent colonoscopy, and the main manifestations under endoscopy were the ulceration type (24 cases). The ulcers were irregular at the edges and often covered with moss at the bottom. The median survival time was 4.3 months. Multivariate Cox regression analysis showed that hemocytic syndrome (HR=8.50,95% CI: 1.679-8.328,P=0.001), serum albumin (HR=3.59,95% CI: 1.017-6.551, P=0.048), and with or without chemotherapy (HR=0.31, 95% CI: 0.246-1.061, P=0.025) were independent factors influencing the overall survival of patients with colorectal extranodal NK/T cell lymphoma. Conclusions: Colorectal extranodal NK/T cell lymphoma is a rare disease with a very poor prognosis. When patients present with abdominal pain and lymphoma B symptoms, and when ulcers with irregular edges and moss covering the bottom are found under endoscopy, the disease should be considered, and endoscopic biopsy should be taken in time for pathological diagnosis. The prognosis of patients with hemophagocytic syndrome and hypoproteinemia is poor. This disease should be treated with chemotherapy and surgery, and on this basis, hemophagocytic syndrome and hypoproteinemia should be treated to improve the prognosis of patients.
Sujet(s)
Coloscopie , Tumeurs colorectales , Lymphome T-NK extraganglionnaire , Humains , Mâle , Lymphome T-NK extraganglionnaire/anatomopathologie , Lymphome T-NK extraganglionnaire/diagnostic , Femelle , Études rétrospectives , Pronostic , Tumeurs colorectales/anatomopathologie , Douleur abdominale/étiologie , Taux de survie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Cyclophosphamide/administration et posologie , Cyclophosphamide/usage thérapeutique , Fièvre/étiologie , Perforation intestinale/étiologie , Adulte d'âge moyen , Vincristine/usage thérapeutiqueRÉSUMÉ
Premature ovarian insufficiency (POI), a major cause of female infertility, is defined as follicular atresia and a rapid loss of germ cells in women of reproductive age due to ovarian failure. Recently, findings from several studies have indicated that human umbilical cord mesenchymal stem cells (hUMSCs) can alleviate ovarian dysfunction resulting from POI. However, the mechanisms underlying this effect require further clarification. In this study, a mouse model of POI was established as achieved with an intraperitoneal injection of cyclophosphamide (CTX) into female C57BL/6J mice in vivo. These POI mice received a 1-week intervention of hUMACs. In addition, an in vitro POI model was also included. The cultured supernatants of hUMSCs and glycogen synthase kinase 3 beta (GSK3ß) inhibitor (SB216763) were used to treat theca cells (TCs) exposed to CTX. Hematoxylin and Eosin (H&E) staining and Enzyme-linked immunosorbent assay (ELISA) were used to assess ovarian structure and morphology, as well as endocrine function in these POI mice. Based on results from the ELISA and JC-1 labeling, CTX exerted significant detrimental effects on testosterone levels and the mitochondrial membrane potential in TCs. Subsequently, Western Blot, Immunofluorescence staining (IF), and Quantitative real-time polymerase chain reaction (qRT-PCR) were used to evaluate various indicators of testosterone synthesis function and mitochondrial dynamics in ovaries and TCs of POI mice. In vivo, dysfunctions in ovarian structure and function in the POI mouse model were effectively restored following hUMSCs treatment, and abnormalities in hormone synthesis were significantly reduced. Furthermore, when the stem cell supernatants of hUMSCs were applied to TCs in vitro we found that GSK3ß expression was reduced, the imbalance of mitochondrial dynamics was alleviated, and the ability of mitochondrial testosterone synthesis was increased. Taken together, our results indicate that hUMSCs treatment can restore the imbalance of mitochondrial dynamics and restart testosterone synthesis of TCs by suppressing GSK3ß expression, ultimately alleviating POI damage.
Sujet(s)
Glycogen synthase kinase 3 beta , Cellules souches mésenchymateuses , Dynamique mitochondriale , Insuffisance ovarienne primitive , Cellules thécales , Animaux , Femelle , Glycogen synthase kinase 3 beta/métabolisme , Souris , Cellules thécales/métabolisme , Cellules thécales/effets des médicaments et des substances chimiques , Cellules souches mésenchymateuses/métabolisme , Humains , Insuffisance ovarienne primitive/métabolisme , Insuffisance ovarienne primitive/thérapie , Dynamique mitochondriale/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Souris de lignée C57BL , Ovaire/métabolisme , Ovaire/effets des médicaments et des substances chimiques , Cordon ombilical/cytologie , Cyclophosphamide/pharmacologie , Transplantation de cellules souches mésenchymateuses/méthodes , Mitochondries/métabolisme , Mitochondries/effets des médicaments et des substances chimiques , Testostérone , Potentiel de membrane mitochondriale/effets des médicaments et des substances chimiques , Indoles , MaléimidesSujet(s)
Cyclophosphamide , Granulomatose avec polyangéite , Rituximab , Humains , Rituximab/usage thérapeutique , Cyclophosphamide/usage thérapeutique , Granulomatose avec polyangéite/traitement médicamenteux , Granulomatose avec polyangéite/diagnostic , Résultat thérapeutique , Femelle , Mâle , Adulte d'âge moyen , Immunosuppresseurs/usage thérapeutique , Induction de rémission , Adulte , Facteurs temps , Chimiothérapie d'induction , Sujet âgé , Études rétrospectivesRÉSUMÉ
Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma. Patients with hemophagocytic lymphohistiocytosis (HLH)-associated IVLBCL variants exhibit significantly poor survival. Cytokines play pivotal roles in malignancy-associated HLH as well as in capillary leak syndrome (CLS). The pathogenesis of CLS involves hyperpermeability and transient endothelial dysfunction. Here, we report the first case of HLH-associated IVLBCL variant complicated with CLS. The patient presented with fever, refractory hypoproteinemia, hypotension and severe edema, followed by telangiectasias. Treatment with etoposide and dexamethasone and hydroxyethyl starch-based artificial colloid led to transient improvement. The diagnosis of IVLBCL was confirmed after the sixth bone marrow biopsy. Subsequently, the R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone) regimen was administered and resulted in prompt alleviation of CLS and HLH symptoms. The patient has survived for more than 6 years after combination of immunochemotherapy and autologous peripheral stem-cell transplantation. This case provides some insights into the mechanism and clinical management of IVLBCL complicated with HLH and CLS. Similar cases concerning lymphoma-associated CLSs were also reviewed.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Syndrome de fuite capillaire , Lymphohistiocytose hémophagocytaire , Lymphome B diffus à grandes cellules , Humains , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/étiologie , Lymphohistiocytose hémophagocytaire/complications , Lymphohistiocytose hémophagocytaire/traitement médicamenteux , Syndrome de fuite capillaire/étiologie , Syndrome de fuite capillaire/diagnostic , Syndrome de fuite capillaire/thérapie , Lymphome B diffus à grandes cellules/complications , Lymphome B diffus à grandes cellules/traitement médicamenteux , Lymphome B diffus à grandes cellules/diagnostic , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Vincristine/usage thérapeutique , Mâle , Cyclophosphamide/usage thérapeutique , Prednisone/usage thérapeutique , Doxorubicine/usage thérapeutique , Doxorubicine/administration et posologie , Rituximab/usage thérapeutique , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Extranodal natural killer/T-cell lymphoma (ENKTL) with tonsil involvement is not common, especially in children. CASE PRESENTATION: A 13-year-old girl presented with an unexplained sore throat for more than 2 months, together with intermittent fever and suppurative tonsilitis. Nasopharyngoscopy revealed a pharyngeal mass. Enhanced computed tomography (CT) scan showed tonsillar hypertrophy and punctate calcification. Chronic pyogenic granulomatous inflammation with pseudoepithelial squamous epithelial hyperplasia was observed in left tonsil, and pyogenic granulomatous inflammation and a small number of T-lymphoid cells were detected in the right tonsil. The immunohistochemical results showed CD2+, CD3+, CD4+, CD5+, CD8+, granzyme B+, and TIA-1+. The Ki-67 proliferation index was 20%. The case showed T cell receptor gene rearrangement. Finally, the case was diagnosed as ENKTL of stage II with tonsil involvement. The patient received 6 cycles of chemotherapy with SMILE regimen, and showed complete response with no recurrence in the follow-up. CONCLUSION: We presented a rare case of ENKTL with tonsil involvement in a child. The patient showed complete response to the SMILE chemotherapy with no recurrence.
Sujet(s)
Lymphome T-NK extraganglionnaire , Tumeurs de l'amygdale , Humains , Femelle , Adolescent , Lymphome T-NK extraganglionnaire/anatomopathologie , Tumeurs de l'amygdale/anatomopathologie , Tumeurs de l'amygdale/imagerie diagnostique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tonsille palatine/anatomopathologie , Amygdalite/anatomopathologie , Amygdalite/traitement médicamenteux , Amygdalite/imagerie diagnostique , Études de suivi , Réarrangement des gènes des lymphocytes T , Pharyngite/anatomopathologie , Vincristine/usage thérapeutique , Tomodensitométrie , Cyclophosphamide/usage thérapeutiqueRÉSUMÉ
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a complex chronic pain disorder with an elusive etiology and nonspecific symptoms. Although numerous animal models with phenotypes similar to human disease have been established, no available regimen can consistently alleviate clinical symptoms. This dilemma led us to question whether current animal models adequately represent IC/BPS. We compared four commonly used IC/BPS rat models to determine their diverse histopathological and molecular patterns. Female rats were given single treatments with hydrochloric acid (HCL), acetic acid (AA), protamine sulfate plus lipopolysaccharide (PS + LPS), or cyclophosphamide (CYP) to induce IC/BPS. Bladder sections were stained for histopathologic evaluation, and mRNA expression profiles were examined using next-generation sequencing and gene set analyses. Mast cell counts were significantly higher in the HCL and AA groups than in the PS + LPS, CYP, and control groups, but only the AA group showed significant collagen accumulation. The models differed substantially in terms of their gene ontology and Kyoto encyclopedia of genes and genomes pathways. Our observations suggest that none of these rat models fully reflects the complexity of IC/BPS. We recommend that future studies apply and compare multiple models simultaneously to fully replicate the complicated features of IC/BPS.
Sujet(s)
Cystite interstitielle , Modèles animaux de maladie humaine , Animaux , Cystite interstitielle/anatomopathologie , Cystite interstitielle/induit chimiquement , Cystite interstitielle/métabolisme , Femelle , Rats , Vessie urinaire/anatomopathologie , Vessie urinaire/métabolisme , Vessie urinaire/effets des médicaments et des substances chimiques , Rat Sprague-Dawley , Mastocytes/métabolisme , Cyclophosphamide/effets indésirables , Acide chlorhydrique/effets indésirables , Acide chlorhydrique/toxicité , LipopolysaccharidesRÉSUMÉ
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for acquired aplastic anemia (acquired AA) in young patients. The objective of the study was to compare patient outcomes after Cyclophosphamide and horse antithymocyte globulin (Cy-hATG) versus Fludarabine-cyclophosphamide and rabbit ATG (Flu-Cy-rATG) as part of conditioning regimen in allo-HSCT for acquired AA. RESEARCH DESIGN AND METHODS: Descriptive retrospective study conducted on patients with acquired AA who received allo-HSCT from HLA-matched sibling donors between January 2008 and August 2022 after conditioning regimen with Cy-hATG or Flu-Cy-rATG. RESULTS: A total of 121 patients were enrolled. Cumulative incidence of graft failure was 11.2% in Cy-hATG and 5.3% Flu-Cy-rATG group. There were no significant differences between the two groups in terms of acute GVHD, chronic GVHD, and transplant related mortality. Flu-Cy-rATG group was associated with significantly higher CMV and EBV reactivation(s) compared to Cy-hATG group (p = 0.008 and 0.035, respectively). After a median follow-up of 58 months, estimated overall survival, event-free survival, and graft rejection-free survival were not statistically different between the two groups. CONCLUSIONS: In high-risk population, Flu-Cy-rATG is associated with comparable outcomes to Cy-hATG in allo-HSCT from MSD. However, it seems to be associated with significant risk of viral infections.
Sujet(s)
Anémie aplasique , Sérum antilymphocyte , Cyclophosphamide , Transplantation de cellules souches hématopoïétiques , Fratrie , Conditionnement pour greffe , Vidarabine , Humains , Anémie aplasique/thérapie , Anémie aplasique/mortalité , Transplantation de cellules souches hématopoïétiques/effets indésirables , Transplantation de cellules souches hématopoïétiques/méthodes , Sérum antilymphocyte/usage thérapeutique , Cyclophosphamide/usage thérapeutique , Conditionnement pour greffe/méthodes , Mâle , Femelle , Vidarabine/analogues et dérivés , Vidarabine/usage thérapeutique , Vidarabine/administration et posologie , Animaux , Adolescent , Études rétrospectives , Adulte , Equus caballus , Lapins , Enfant , Transplantation homologue , Donneurs de tissus , Jeune adulte , Maladie du greffon contre l'hôte/étiologie , Maladie du greffon contre l'hôte/prévention et contrôle , Enfant d'âge préscolaire , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: Surface contamination with antineoplastic drugs (ADs) is persistent. The use of personal protective equipment (PPE) is recommended to reduce exposure to ADs. OBJECTIVES: This study explored the impact of the COVID-19 pandemic on nurses' PPE use and surface contamination with ADs. METHODS: Demographic characteristics, PPE use, and associated factors were assessed on two inpatient oncology units where etoposide and cyclophosphamide were administered before (N = 26) and during the COVID-19 pandemic (N = 31). FINDINGS: PPE use when handling contaminated excreta was significantly higher during the pandemic. Perceived risk of chemotherapy exposure was significantly associated with greater PPE use when handling AD-contaminated excreta, and conflict of interest was related to less PPE use during AD administration and handling of AD-contaminated excreta. During the pandemic, surface contamination with etoposide increased in shared areas and decreased in patient rooms.
Sujet(s)
Antinéoplasiques , COVID-19 , Équipement de protection individuelle , Humains , COVID-19/prévention et contrôle , Femelle , Mâle , Antinéoplasiques/usage thérapeutique , Adulte , Adulte d'âge moyen , Pandémies , SARS-CoV-2 , Exposition professionnelle/prévention et contrôle , Soins infirmiers en oncologie/normes , Étoposide/usage thérapeutique , Cyclophosphamide/usage thérapeutique , Personnel infirmier hospitalierRÉSUMÉ
BACKGROUND: Dogs with lymphoma that fail cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (CHOP) before completion of their protocol are commonly thought to have poor long-term outcome, but no previous studies have evaluated the effect of early relapse on progression-free interval (PFI) or overall survival time (OST) for patients undergoing rescue chemotherapy. OBJECTIVE: Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy. METHODS: Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase. RESULTS: The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB. CONCLUSION: Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Cyclophosphamide , Maladies des chiens , Doxorubicine , Lymphomes , Prednisone , Vincristine , Animaux , Chiens , Maladies des chiens/traitement médicamenteux , Vincristine/usage thérapeutique , Cyclophosphamide/usage thérapeutique , Cyclophosphamide/administration et posologie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Prednisone/usage thérapeutique , Prednisone/administration et posologie , Doxorubicine/usage thérapeutique , Femelle , Mâle , Lymphomes/médecine vétérinaire , Lymphomes/traitement médicamenteux , Asparaginase/usage thérapeutique , Résultat thérapeutique , Études rétrospectives , Lomustine/usage thérapeutique , Évolution de la maladie , Études prospectives , Alanine/analogues et dérivés , PurinesRÉSUMÉ
The progression and pathogenesis of membranous glomerulonephritis (MGN) are inextricably linked to chronic inflammation. Despite improving clinical remission rates due to the application of cyclophosphamide (CYC), treatment of MGN still requires further exploration. Ruxolitinib (Ruxo) negatively affects the signaling pathways participating in the production of pro-inflammatory cytokines. Hence, we investigated whether the combination of CYC and Ruxo can modulate inflammation through influencing T helper 17 (Th17) lineages and regulatory T cells (Tregs). Passive Heymann nephritis (PHN), an experimental model of MGN, was induced in a population of rats. Then, the animals were divided into five groups: PHN, CYC-receiving, Ruxo-receiving, CYC-Ruxo-receiving PHN rats, and healthy controls. After 28 days of treatment, biochemistry analysis was performed and splenocytes were isolated for flowcytometry investigation of Th17 cells and Tregs. The correlative transcription factors of the cells, alongside their downstream cytokine gene expressions, were also assessed using real-time PCR. Furthermore, serum cytokine signatures for the lymphocytes were determined through ELISA. The combination of CYC and Ruxo significantly reduced the serum values of urea in rats versus the PHN group (24.62 ± 7.970 vs. 40.60 ± 10.81 mg/dL). In contrast to Treg's activities, the functionality of Th17 cells noticeably increased not only in PHN rats but also in CYC or Ruxo-receiving PHN animals when compared with the control (10.60 ± 2.236, 8.800 ± 1.465, 8.680 ± 1.314 vs. 4.420 ± 1.551 %). However, in comparison to the PHN group, the incidence of Th17 cells notably fell in rats receiving CYC and Ruxo (10.60 ± 2.236 vs. 6.000 ± 1.373 %) in favor of the Treg's percentage (5.020 ± 1.761 vs. 8.980 ± 1.178 %), which was verified by the gene expressions and cytokine productions correlative to these lymphocytes. The combination of CYC and Ruxo was able to decline Th17 cells in favor of Tregs improvement in PHN rats, suggesting an innovative combination therapy in MGN treatment approaches.
Sujet(s)
Cyclophosphamide , Cytokines , Glomérulonéphrite extra-membraneuse , Nitriles , Pyrazoles , Pyrimidines , Lymphocytes T régulateurs , Cellules Th17 , Animaux , Glomérulonéphrite extra-membraneuse/traitement médicamenteux , Glomérulonéphrite extra-membraneuse/immunologie , Lymphocytes T régulateurs/effets des médicaments et des substances chimiques , Lymphocytes T régulateurs/immunologie , Cellules Th17/effets des médicaments et des substances chimiques , Cellules Th17/immunologie , Cyclophosphamide/pharmacologie , Cyclophosphamide/usage thérapeutique , Nitriles/pharmacologie , Nitriles/usage thérapeutique , Pyrimidines/pharmacologie , Pyrimidines/usage thérapeutique , Rats , Pyrazoles/pharmacologie , Pyrazoles/usage thérapeutique , Cytokines/métabolisme , Mâle , Modèles animaux de maladie humaine , Association de médicamentsRÉSUMÉ
OBJECTIVES: In this six-year follow-up study, we used patient-reported outcome measures (PROMs) to compare values at baseline, at 18 months, and at six-year follow up from the CycloME and the RituxME trials. METHODS: Based on the hypothesis that ME/CFS in a subgroup of patients is a variant of an autoimmune disease, we performed two clinical trials between 2014 and 2017. The RituxME trial was a randomized, double-blind and placebo-controlled phase III trial of 151 patients, assessing the B-cell depleting antibody rituximab. The CycloME trial was an open-label phase II trial of 40 patients using intravenous cyclophosphamide. Here we report six-year follow-up from both trials, using the Short Form 36 Physical Function (SF-36 PF) and DePaul short form (DSQ-SF) questionnaires. RESULT: Of the patients available after six years, 75.7% of RituxME and 94.4% of CycloME patients participated. In the RituxME rituximab group, the mean SF-36 PF scores were 32.9 at baseline, 42.4 at 18 months and 45.5 at six years. In the placebo group, the mean SF-36 PF scores were 32.3 at baseline, 45.5 at 18 months and 43.1 at six years. In the CycloME trial, mean SF-36 PF increased from 35.4 at baseline to 54.4 at 18 months, and 56.7 at six years. At six-year follow-up, 44.1% of cyclophosphamide-, 27.6% of rituximab- and 20.4% of placebo-treated patients had an SF-36 PF ≥ 70, and further, 17.6%, 8.6% and 7.4% of the corresponding patient groups had an SF-36 PF ≥ 90, which is within normal range. In terms of worsening at six years, 5.9% of cyclophosphamide-treated, 10.3% of rituximab-, and 14.8% of placebo-treated patients had a drop in SF-36 PF of 20 points or more from baseline. There were no serious unexpected adverse reactions. CONCLUSIONS: After six years, 44.1% of the cyclophosphamide group scored an SF-36 PF of at least 70, and 17.6% of at least 90, suggesting that cyclophosphamide in a subgroup may modulate the disease course in a beneficial way. However, cyclophosphamide carries toxicity concerns and should not be used for ME/CFS patients outside clinical trials. Rather, these data should encourage efforts to better understand the disease mechanisms and to search for targeted and less toxic immune modulatory treatment for this patient group.